Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Allogene Therapeutics, Inc. - Common Stock (NQ:ALLO)

1.190 -0.010 (-0.83%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Allogene Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Earnings Scheduled For May 13, 2025
Via Benzinga
Allogene Therapeutics's Earnings Outlook
Via Benzinga
Earnings Scheduled For March 13, 2025
Via Benzinga
A Closer Look at 6 Analyst Recommendations For Allogene Therapeutics
Via Benzinga
Analyst Ratings For Allogene Therapeutics
Via Benzinga
Allogene Short Interest Reportedly Near 5-Year Lows Amid Growing Retail Optimism: Analyst Sees CAR-T Therapy Promise
Baird remains bullish on Allogene, stating that the updated cema-cel data continues to support the "differentiated durability" of its allogeneic CAR-T therapy. 
Via Stocktwits
Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Tuesday's session: gap up and gap down stocks
In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
Friday's session: top gainers and losers
Here are the top movers in Friday's session, showcasing the stocks with significant price changes. 
Via Chartmill
Breaking Down Allogene Therapeutics: 5 Analysts Share Their Views
Via Benzinga
Recap: Allogene Therapeutics Q4 Earnings
Via Benzinga
Allogene Therapeutics Earnings Preview
Via Benzinga
What's going on in today's session
Here are the top movers in Friday's session, showcasing the stocks with significant price changes. 
Via Chartmill
Friday's session: gap up and gap down stocks
The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
7 Biotech Stocks to Buy for Their Game-Changing Potential
Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks. 
Via InvestorPlace
Cell Therapy Mostly Used For Blood Cancer Shows Efficacy In Autoimmune Diseases As Well, But There Are Challenges
CAR-T therapy, originally used for blood cancers, shows promising results in treating lupus, as evidenced by Janina Paech's remarkable remission. This breakthrough offers new hope for autoimmune... 
Via Benzinga
If You Can Only Buy One Penny Stock in May, It Better Be One of These 3 Names
Penny stocks to buy carry a great deal of risk. However, there are a few that look interesting after due diligence. 
Via InvestorPlace
Why James Hardie Industries Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Larimar Therapeutics Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
Via Benzinga
DLocal, Allogene Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
ALLO Stock Earnings: Allogene Therapeutics Beats EPS, Beats Revenue for Q1 2024
ALLO stock results show that Allogene Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation
Via Benzinga
Topics ETFs
3 Meme Stocks to Sell and Replace With Meme Coins
For investors who want to avoid losses, sell or avoid certain meme stocks that are on the radar for potential sell-offs. 
Via InvestorPlace
ALLO Stock Earnings: Allogene Therapeutics Misses EPS, Beats Revenue for Q4 2023
ALLO stock results show that Allogene Therapeutics missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
CymaBay Therapeutics, ContextLogic, Snap And Other Big Stocks Moving Higher On Monday
U.S. stocks were mixed, with the Nasdaq Composite trading almost flat on Monday. Shares of CymaBay Therapeutics, Inc. (NASDAQ: CBAY) rose sharply in today’s pre-market trading. 
Via Benzinga
Topics Stocks
Earnings Scheduled For March 14, 2024
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter. 
Via Benzinga
Cell Therapy Focused Allogene Therapeutics' Resource Prioritization A Bold Move, Says Analyst
Allogene Therapeutics Inc (NASDAQ: ALLO) announced deprioritizing the currently enrolling third line Phase 2 ALPHA2 and EXPAND trials of cema-cel (ALLO-501A) and is now pursuing a potentially pivotal... 
Via Benzinga
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Applied Therapeutics, Inc. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.